BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28922951)

  • 1. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
    Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
    Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
    Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
    Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients.
    Chaves DG; Velloso-Rodrigues C; Oliveira CA; Teixeira-Carvalho A; Santoro MM; Martins-Filho OA
    Clin Exp Immunol; 2010 Dec; 162(3):425-37. PubMed ID: 20846164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K; Shetty S
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.
    Wroblewska A; van Haren SD; Herczenik E; Kaijen P; Ruminska A; Jin SY; Zheng XL; van den Biggelaar M; ten Brinke A; Meijer AB; Voorberg J
    Blood; 2012 May; 119(22):5294-300. PubMed ID: 22498747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
    Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
    Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
    Samelson-Jones BJ; Arruda VR
    Front Immunol; 2020; 11():618. PubMed ID: 32425925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.
    Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM
    Blood; 2005 Nov; 106(10):3415-22. PubMed ID: 16091456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.